ArticleScientific reports2025
Improving retinal vessel assessment precision by integrating deep learning with interactive editing and graphical modeling.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence assisted quantitative analysis of fundus structural and vascular alterations reveals fundus tessellation as a robust biomarker of myopia severity.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
We present the SEoul Retinal Vessel Assessment Library (SERVAL), a novel software platform for precise quantitative measurement of vascular structures in fundus images. SERVAL integrates deep learning-based automatic artery and vein mask initialization, subpixel vessel centerline and boundary refinement, and interactive editing tools within a user-friendly graphical interface. From the refined artery and vein delineations, it enables accurate computation of a wide range of vessel assessment metrics, facilitating better characterization of complex vascular structures. We evaluate SERVAL through: (1) comparative analyses with existing platforms, highlighting its superior precision and structural detail; (2) longitudinal image studies demonstrating measurement consistency; and (3) a usability study confirming its clinical practicality. We expect SERVAL to serve as a valuable tool in clinical research, supporting the development of novel vascular biomarkers and diagnostic metrics for retinal and systemic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.